78013

Study of cytotoxic activity by T CD4+ lymphocytes in patients with Secondary Progressive Multiple Sclerosis.

Favoritar este trabalho

Introduction: Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects about 2.5 million people worldwide. MS usually begins in a relapsing-remitting manner (RRMS), but after a few years, when neurological damage reaches a certain limit, patients develop the secondary progressive form of disease (SPMS). There are several therapeutic strategies available for treatment of RRMS, but a specific drug therapy for SPMS is still lacking. It has been long suggested that cytotoxic activity is involved in CNS damage during MS. Here we aimed to investigate cytotoxic activity measuring granzyme B (GzmB)-derived T lymphocytes during SPMS. Methods: Eight SPMS patients were recruited according to clinical criteria and ten healthy subjects were used as control group. Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque gradient and labeled for flow cytometry. Results and Discussion: Maybe due to our small cohort, we didn’t found increased GzmB-production by CD8+ T lymphocytes in SPMS patients. Yet, surprisingly, GzmB-derived T CD4+ lymphocytes were found about 6-fold higher in SPMS patients than in healthy subjects. Conclusion: Cytotoxic activity in peripheral blood of SPMS patients still needs further investigation. Also, deeper knowledge into inflammatory profile may provide evidence for development of specific drug-target, monitoring disease progression and therapeutic response during MS course.